The Board of Gavi, the Vaccine Alliance today outlined a set of decisions that will expand the portfolio of vaccine programmes available to lower-income countries in the coming years. Hexavalent vaccine: The Board approved Gavi investment in the six-in-one vaccine – a combination of the pentavalent vaccine, which protects against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, and the inactivated polio vaccine (IPV). 2024 Vaccine Investment Strategy: Looking further ahead, the Board also approved a long list of vaccines to be considered for inclusion in Gavi’s next Vaccine Investment Strategy, which will be finalised by 2024. The Secretariat further reported on plans underway to ensure “day zero” financing for future pandemic vaccine response. “With more than 1 billion unique children reached, one eighth of humanity has now been protected by the Vaccine Alliance.

Source: News Business Ethiopia June 29, 2023 08:58 UTC